2006
DOI: 10.1016/j.ejphar.2006.06.068
|View full text |Cite
|
Sign up to set email alerts
|

Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
57
1
2

Year Published

2006
2006
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 75 publications
(66 citation statements)
references
References 27 publications
5
57
1
2
Order By: Relevance
“…These are c-Kit-expressing cells that may be related to the interstitial Cajal cells of the gut, which mediate rhythmic activity in smooth muscle cells (40). The activity of these cells can be inhibited by imatinib (41).…”
Section: Discussionmentioning
confidence: 99%
“…These are c-Kit-expressing cells that may be related to the interstitial Cajal cells of the gut, which mediate rhythmic activity in smooth muscle cells (40). The activity of these cells can be inhibited by imatinib (41).…”
Section: Discussionmentioning
confidence: 99%
“…In various other smooth muscles, imatinib predominantly reduces the amplitude of spontaneous contractions without altering their frequency. 12,13) Recently, Hashitani et al 15) suggested that imatinib inhibited the slow wave but not inhibited the frequency in the guinea pig corpus. Therefore, we think that this phenomenon is specific to imatinib and imatinib may not affect the initial component of pacemaker potentials.…”
Section: Discussionmentioning
confidence: 99%
“…10) As both development and maintenance of ICC require Kit, 11) an inhibitor of Kit signaling could be used as a specific blocker for the function of ICC. Recently, imatinib mesylate has been shown to suppress contractile activity in various phasic smooth muscles, including the human uterus and small intestine, 12) guinea-pig bladder, 13) guinea-pig gall bladder 14) and guinea pig stomach. 15) However, none of the studies has demonstrated that the effects of imatinib mesylate, on pacemaker potentials in ICC.…”
mentioning
confidence: 99%
“…Recently STI571 (Glivec, Novartis, Basel, Switzerland), a tyrosine kinase inhibitor, was found to have a favorable therapeutic effect on metastatic GIST and c-Kit expression in tumor cells became an important criterion in the diagnosis as well as the management of GIST [67][68][69]. Moreover, Glivec was proved to inhibit spontaneous rhythmic contractions of human intestine and also in human uterus, perhaps via ligand-independent c-kit/CD117 tyrosine-kinase signaling [70].…”
Section: Molecular Biology Of Iccmentioning
confidence: 99%